Long-term hydroxyurea therapy in beta-thalassaemia patients

European Journal of Haematology

Volumn 70, Issue 3, 2003, Pages 151-155

  De Paula, Erich Vinicius ^a   Lima, Carmen Silvia Passos ^a   Arruda, Valder Roberval ^a   Alberto, Fernando Lopes ^a   Saad, Sara Teresinha Ollala ^a   Costa, Fernando Ferreira ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Beta thalassaemia; Hydroxyurea; Therapy

Indexed keywords

HEMOGLOBIN F; HYDROXYUREA; LIVER ENZYME;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; BLOOD CELL COUNT; CLINICAL ARTICLE; CORRELATION ANALYSIS; DRUG EFFECT; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; LONG TERM CARE; MALE; MEAN CORPUSCULAR HEMOGLOBIN; PRIORITY JOURNAL; RETICULOCYTE COUNT;

ADOLESCENT; ADULT; AGED; BETA-THALASSEMIA; BLOOD CELL COUNT; CREATINE; ENZYME TESTS; ERYTHROCYTE INDICES; FETAL HEMOGLOBIN; HEMOGLOBINS; HUMANS; HYDROXYUREA; LIVER; MALE; RETICULOCYTE COUNT;

EID: 0038137049     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2003.00037.x     Document Type: Article

References (32)

1. HIGGS DR, THEIN SL, WOODS WG. The physiology of the thalassemia. In WEATHERALL DJ, CLEGG B, eds. The Thalassemia Syndromes, 4th edn. Oxford: Blackwell Science Ltd, 2001:265-284.
2. ATWEH GF, LOUKOPOULOS D. Pharmacological induction of fetal hemoglobin in sickle cell disease and beta-thalassemia. Semin Hematol 2001;38:367-373.
3. + thalassemia. N Engl J Med 1982;307:1469-1475.
4. LOWERY CH, NIENHUIS AW. Treatment with azacytidine of patients with end-stage β thalassemia. N Engl J Med 1993;329:845-848.
5. FIBACH E, BURKE LP, SCHECHTER AN, NOGUSJ CT, RODGERS GP. Hydroxyurea increases fetal hemoglobin in cultured erythroid cells derived from normal individuals and patients with sickle cell anemia. Blood 1993;81:1630-1635.
6. CHARACHE S, TERRIN ML, MOORE RD, et al. Effects of hydroxyurea on the frequency of painful crisis in sickle cell anemia. N Engl J Med 1995;332:1317-1322.
7. LIMA CSP, ARRUDA VR, SAAD STO, COSTA FF. Minimal doses of hydroxyurea for sickle cell disease. Braz J Med Biol Res 1997;30:933-940.
8. DOVER GJ, CHARACHE S. Hydroxyurea induction of fetal hemoglobin synthesis in sickle cell disease. Semin Oncol 1992;19:61-66.
9. ATWEH GF, LOUKOPOULOS D. Pharmacological induction of fetal hemoglobin in sickle cell disease and β-thalassemia, Semin Hematol 2001;38:367-373.
10. NIENHUIS AW, LEY TJ, HUMPHRIES RK, YOUNG NS, DOVER G. Pharmacological manipulation of fetal hemoglobin synthesis in patients with severe beta-thalassemia. Ann N Y Acad Sci 1985;445:198-211.
11. MCDONAGH KT, ORRINGER EP, DOVER GJ, NIENHUS AW, Hydroxyurea improves erythropoiesis in a patient with homozygous beta-thalassemia. Clin Res 1990;38:346A.
12. HAJJAR FM, PEARSON HA. Pharmacologic treatment of thalassemia intermedia with hydroxyurea. J Pediatr 1994;125:490-492.
13. ZENG YT, HUANG SZ, REN ZR, et al. Hydroxyurea therapy in β-thalassemia intermedia: improvement in haematological parameters due enhanced β-globin synthesis. Br J Haematol 1995;90:557-563.
14. FUCHAROEN S, SIRITANARATKUL N, WINICHAGOON P, et al. Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease. Blood 1996;87:887-892.
15. ACKER M, RACHMILEWITZ EA. Long-term erythropoietic response to hydroxyurea (28 weeks) in β thalassemia intermedia is unchanged by adding low dose erythropoietin (18 weeks) Blood 1996;10:2816.
16. ARRUDA VR, LIMA CSP, SAAD STO, COSTA FF. Successful use of hydroxyurea in β-thalassemia major. N Engl J Med 1997;336:964.
17. CHOUDHRY VP, LAL A, PATI HP, ARYA LS. Hematological responses to hydroxyurea therapy in multitransfused thalassemic children. Indian. J Pediatr 1997;64:3953-8.
18. LOUKOPOULOS D, VOSKARIDOU E, STAMOULAKATOU A, et al. Hydroxyurea therapy in thalassemia. Ann N Y Acad Sci 1998;850:120-128.
19. SAXON BR, REES D, OLIVIERI NF. Regression of extramedullary haemopoiesis and augmentation of fetal haemoglobin concentration during hydroxyurea therapy in beta thalassaemia. Br J Haematol 1998;101:416-419.
20. STYLES L, LEWIS B, FOOTE D, CUCA L, VICHINSKY E. Preliminary report: hydroxyurea produces significant clinical response in thalassemia intermedia. Ann N Y Acad Sci 1998;850:461-462.
21. HOPPE C, VICHINSKY E, LEWIS B, FOOTE D, STYLES L. Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia. Am J Hematol 1999;62:221-227.
22. TSIARTA H, PAVLIDIDS N, VOSKARIDOU E. Treatment of thalassemia intermedia with hydroxyurea. Blood 1999;94:3309.
23. CIANCIULLI P, DI TORITTO TC, SORRENTINO F, SERGIACOMI L, MASSA A, AMADORI S. Hydroxyurea therapy in paraparesis and cauda equine syndrome due to extramedullary haematopoiesis in thalassaemia: improvement of clinical and haematological parameters. Eur J Haematol 2000;64:426-429.
24. EL ALFY MS, TANTAWY AAG. One year pilot trial of hydroxyurea in transfusion dependant pediatric β thalassemia intermedia. Blood 2000;96:3759.
25. CARIO H, WEGENER M, DEBATIN KM, KOHNE E. Treatment with hydroxyurea in thalassemia intermedia with paravertebral pseudotumors of extramedullary hematopoiesis. Ann Hematol 2002;81:478-482.
26. OLD JM, OLIVlERI NF, THEIN SL. The laboratory diagnosis of the thalassemias. In WEATHERALL DJ, CLEGG, Beds. The Thalassemia Syndromes, 4th edn. Oxford: Blackwell Science Ltd, 2001:597-723.
27. GRIGNOLI CR, CARVALHO MH, KIMURA EH, et al. Beta thalassemia resulting from a novel mutation: beta/u-stopo codon. Eur J Haematol 2000;64:137-138.
28. BAIN B. Basic haematological techniques. In DACIE JV, LEWIS SM, eds. Practical Haematology, 8th edn. Hong Kong, Churchill Livingstone, 1995:49-82.
29. BROZOVIC M, HENTHORN J. Investigation of abnormal haemoglobins and thalassaemia. In DACIE JV, LEWES SM, eds. Practical Haematology, 8th edn. Hong Kong, Churchill Livingstone, 1995:249-286.
30. DOVER GJ. Hemoglobin switching protocols in thalassemia. Ann NY Acad Sci 1998;850:80-86.
31. ALTMAN DG. Practical Statistics for Medical Research. London: Chapman & Hall, 1991:611.
32. FERSTER A, TAHRIRI P, VERMYLEN C, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 2001;97:3628-3632.